Strata Acquires Louisville Perfusion Services
Rhea-AI Summary
Strata Critical Medical (Nasdaq: SRTA) completed the all-cash acquisition of Louisville Perfusion Services, a regional perfusion and blood management provider in Kentucky. The deal totals about $16 million upfront plus up to $4 million in performance-based consideration.
LPS is expected to generate about $10 million revenue and $3 million Adjusted EBITDA in 2026. The acquisition expands Strata’s cardiac perfusion platform, which serves more than 275 hospitals, and enhances support for organ transplant programs, ECMO services, and regional coverage in the Midwest and Southern United States.
AI-generated analysis. Not financial advice.
Positive
- All-cash acquisition with approximately $16 million upfront consideration
- Up to $4 million additional consideration tied to 12-month performance of LPS
- LPS expected 2026 revenue of about $10 million
- LPS expected 2026 Adjusted EBITDA of about $3 million
- Acquisition aligns with bolt-on M&A at mid-single digit Adjusted EBITDA multiples
- Expands perfusion and transplant service capabilities across more than 275 hospitals
Negative
- None.
News Market Reaction – SRTA
On the day this news was published, SRTA gained 2.29%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SRTA was down 3.01% while key peers were mixed: ASLE -0.61%, UP +13.35%, CAAP +1.67%, OMAB +0.39%. Moves do not indicate a unified sector trend.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Perfusion acquisition | Positive | +1.2% | Closed Ohio Valley Perfusion acquisition at about $1M purchase price. |
| Feb 05 | Credit facility | Positive | -6.2% | Secured up to $30M revolving credit facility to fund acquisitions. |
| Sep 16 | Major acquisition | Positive | +8.2% | Acquired Keystone Perfusion for $124M to expand organ recovery platform. |
Acquisition-related announcements have generally seen small positive stock reactions, with one negative move on financing news.
Over the last year, Strata has used acquisitions to build a perfusion and organ recovery platform. The Keystone Perfusion deal at $124M and the smaller Ohio Valley Perfusion purchase show a tuck-in strategy, supported by a $30M revolving credit facility. Those events often produced modestly positive price reactions. The Louisville Perfusion Services deal extends this bolt-on pattern within cardiac perfusion services.
Historical Comparison
Past acquisition and acquisition-financing updates for SRTA led to an average ±1.06% move, suggesting markets typically react modestly to such bolt-on expansion news.
Strata has progressed from the large Keystone Perfusion purchase to smaller tuck-in acquisitions like Ohio Valley Perfusion, all supported by a dedicated credit facility to execute its acquisition strategy in perfusion and organ transplant services.
Market Pulse Summary
This announcement adds another bolt-on acquisition in perfusion services, with LPS expected to contribute $10 million in revenue and $3 million in Adjusted EBITDA for 2026. It builds on earlier deals like Keystone and Ohio Valley Perfusion, reinforcing Strata’s focus on cardiac and transplant-related services. Investors may monitor how LPS integrates operationally, actual performance against these targets, and any future capital maneuvers used to support continued M&A activity.
Key Terms
perfusion medical
ecmo medical
adjusted ebitda financial
gaap financial
organ transplant medical
organ procurement organizations medical
machine perfusion medical
AI-generated analysis. Not financial advice.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky.
“The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States,” said Lou Verdetto, CEO of Strata’s Clinical Division. “More than just unlocking the ability to win new perfusion contracts in the region, LPS also expands the national footprint of staff and equipment available to support our organ transplant customers.”
“LPS clinicians will serve as preservationists in nearby surgical organ recovery cases and can operate machine perfusion equipment,” said Christie Campbell, Strata’s VP of Cardiac Care. “This will make Strata an even more attractive partner to Transplant Centers and Organ Procurement Organizations.”
"Our customers count on us to be there when it matters most and finding a partner who shares that commitment was my top priority,” said Herbie Eggers, CEO of Louisville Perfusion. “Strata's scale and clinical depth mean our hospital partners will see even stronger coverage and support, with the same people and the same standard of service they already know."
“Adding LPS to Strata's cardiac perfusion platform, which serves more than 275 hospitals today, opens up new capabilities from expanded ECMO support to upgraded technology for the programs LPS serves, positioning the team to make an even bigger impact across the region for years to come,” said Melissa Tomkiel, Co-CEO of Strata.
“This all-cash acquisition is consistent with our M&A strategy of deploying capital towards bolt-on acquisitions at accretive, mid-single digit Adjusted EBITDA multiples that both strengthen our existing service offerings and position Strata for growth,” said Will Heyburn, Co-CEO and CFO of Strata.
The all-cash transaction consists of approximately
(1) We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
About Strata Critical Medical, Inc.
Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.
Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.
For more information, visit https://stratacritical.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", “anticipate”, “believe”, “could”, “continue”, “expect", “estimate”, “may”, “plan”, “outlook”, “future”, "target", and “project” and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Strata’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning Strata’s future plans and business strategies, financial and operating performance (including the discussion of financial outlook and guidance for 2026 and beyond), acquisition opportunities, results of operations, and industry environment and growth opportunities. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Strata’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: our continued net losses or failure to achieve or maintain profitability; our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestment of the Passenger business and acquisition and integration of Keystone; any future acquisitions or partnerships; harm to our reputation and brand; negative publicity, litigation, claims or regulatory scrutiny; our ability to provide high-quality customer support and maintain trusted relationships with customers; our reliance on contractual relationships with transplant centers, hospitals, Organ Procurement Organizations and strategic partners; adoption and effective utilization of our integrated clinical and logistics offerings by medical customers; competition; our dependence on the availability and utilization of organ donors and transplant volumes; insufficient reimbursement or funding for organ transport and related services; risks inherent in organ transportation operations; risks associated with ground transportation operations; advancements in preservation technology or alternative transport methods; aviation safety risks; the effects of climate change, extreme weather events or environmental developments affecting our operations; terrorist attacks, geopolitical conflict or security events affecting aviation or healthcare infrastructure; the volatility in aircraft fuel availability or cost; our ability to obtain additional capital or financing; restrictions under our credit agreement; our ability to manage our growth; insurance market conditions; our dependence on key personnel and our ability to attract and retain qualified professionals; employment-related claims, workforce litigation or labor market challenges; our ability to maintain our company culture as we grow; fluctuations in financial results and the non-comparability of historical financial statements; risks associated with purchasing aircraft or evolving from an asset-light model; risks associated with directly operating aircraft; our reliance on maintaining efficient aircraft utilization to manage costs, operating efficiency and margins; changes in regulatory frameworks; our reliance on third-party aircraft operators; the availability of sufficient third-party aircraft capacity; workforce disruptions, operations interruptions or financial difficulties affecting third-party operators or service workers; risks arising from illegal, improper, or otherwise inappropriate operation of branded aircraft by third-party operators; our reliance on third-party cloud infrastructure, hosting providers and other technology vendors; interruptions, defects, failures or vulnerabilities in our technology systems or those of third-party providers; cybersecurity incidents, data breaches or misuse of artificial intelligence technologies; our ability to protect and enforce intellectual property rights; risks associated with our use of open-source software; our operations within highly regulated environments; the impact of any litigation or regulatory investigations that we may be subject to; our ability to comply with privacy, data protection, consumer protection and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses and maintain effective disclosure controls and procedures; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Strata undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.
Contacts
Mathew Schneider
investors@srta.com
